Several disease modifying treatments (DMTs) are licensed and reimbursed for treating relapsing-remitting multiple sclerosis (RRMS). Cost-effectiveness analyses supporting HTA submissions generally assume that patients discontinuing treatment due to tolerability or disease progression receive best supportive care, assumed to have no effect on RRMS natural history. Contrary, in clinical practice patients receive DMTs in sequence. Results of said cost-effectiveness analyses do not, therefore, sufficiently inform policy regarding optimal use of new drugs. This analysis evaluates the impact on cost-effectiveness of modelling subsequent treatment in RRMS from a UK NHS perspective.
Authors: Phelps H, Treharne C, Ramirez Guevara G, Bertranou E
This is a sneak preview of a poster that will be presented at ISPOR Europe, November 2018. For more information about this poster click here.